PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

PATHOGENETIC MECHANISMS AND TREATMENT PRINCIPLES OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications,...

Full description

Bibliographic Details
Main Authors: N. A. Shostak, A. A. Klimenko, N. A. Demidova, I. V. Novikov
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
pulmonary hypertension
chronic thromboembolic pulmonary hypertension
thromboembolism of pulmonary artery
thromboendarterectomy
bosentan
prostacyclin analogues
phosphodiesterase-5 inhibitors
Online Access:https://www.rpcardio.com/jour/article/view/750
Description
Summary:Data about chronic thromboembolic pulmonary hypertension (CTPH) prevalence is presented. The main CTPH clinical manifestations are described. The possible reasons and pathogenetic mechanisms of CTPH development are discussed. Features of unfavorable disease prognosis are also presented. Indications, results, limitations for CTPH surgical treatment are shown. Data of the currently completed clinical studies on bosentan, prostacyclin analogues and phosphodiesterase-5 inhibitors usage in CTPH are presented.
ISSN:1819-6446
2225-3653

Similar Items